Onderzoeker
Robert Paridaens
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium Experimentele Oncologie (Afdeling)
Lid
Vanaf1 okt 2005 → Heden
Publicaties
1 - 10 of 119 results
- Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials(2020)
Auteurs: Iris Noordhoek, Erik J Blok, Elma Meershoek-Klein Kranenbarg, Hein Putter, Marjolijn Duijm-de Carpentier, Emiel JT Rutgers, Caroline Seynaeve, John MS Bartlett, Jean-Michel Vannetzel, Daniel W Rea, et al.
Pagina's: 3273 - +Aantal pagina's: 12 - Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics(2019)
Auteurs: Veronique Dieras, Herve Bonnefoi, Emilio Alba, Ahmad Awada, Bruno Coudert, Xavier Pivot, Joseph Gligorov, Agnes Jager, Stefania Zambelli, Geoffrey J Lindeman, et al.
Pagina's: 383 - 393Aantal pagina's: 11 - Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer(2019)
Auteurs: Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, et al.
Pagina's: 165 - 171Aantal pagina's: 7 - Tamoxifen metabolism and efficacy in breast cancer– a prospective multicentre trial(2018)
Auteurs: Patrick Neven, Lynn Jongen, A Lintermans, K Van Asten, C Blomme, Diether Lambrechts, A Poppe, Hans Wildiers, Anne-Sophie Dieudonné, O Brouckaert, et al.
Pagina's: 1 - 19 - Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study(2018)
Auteurs: O Brouckaert, K Van Asten, Annouschka Laenen, Adelheid Soubry, Ann Smeets, I Nevelstreen, Ignace Vergote, Hans Wildiers, Robert Paridaens, Erik Van Limbergen, et al.
Pagina's: 189 - 196 - Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials(2018)
Auteurs: JA Alberro, B Ballester, P Deulofeu, R Fabregas, M Fraile, JM Gubern, J Janer, A Moral, JL de Pablo, G Penalva, et al.
Pagina's: 27 - 39Aantal pagina's: 13 - Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial(2017)
Auteurs: Marloes GM Derks, Erik J Blok, Caroline Seynaeve, Johan WR Nortier, Elma Meershoek-Klein Kranenbarg, Gerrit-Jan Liefers, Hein Putter, Judith R Kroep, Daniel Rea, Annette Hasenburg, et al.
Pagina's: 1211 - 1220Aantal pagina's: 10 - Long-Term Follow-Up of the Intergroup Exemestane Study(2017)
Auteurs: James P Morden, Isabel Alvarez, Gianfilippo Bertelli, Alan S Coates, Robert Coleman, Lesley Fallowfield, Jacek Jassem, Stephen Jones, Lucy Kilburn, Per E Lonning, et al.
Pagina's: 2507 - +Aantal pagina's: 10 - Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm(2016)
Auteurs: Lynn Jongen, Robert Paridaens, Giuseppe Floris, Hans Wildiers, Patrick Neven
Pagina's: 603 - 7 - Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients(2015)
Auteurs: Christof Vulsteke, Alena M Pfeil, Charlotte Maggen, Matthias Schwenkglenks, Ruth Pettengell, Thomas D Szucs, Diether Lambrechts, Anne-Sophie Dieudonné, Sigrid Hatse, Patrick Neven, et al.
Pagina's: 67 - 76